-

TheraVet Announces the Commercial Launch of a Local and Sustained Antibiotic Releasing Bone Substitute

  • BIOCERA-VET COMBO-CLEAN, a unique bone substitute for antibiotic delivery:
    • combinable with all main antibiotics covering the usual germs involved in bone infections,
    • providing sustained antibiotic delivery for up to 30 days above MIC1 and,
    • unique osteo-conductive & osteo-integrative properties
  • First successful case already reported

GOSSELIES, Belgium--(BUSINESS WIRE)--Regulatory News:

TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces the commercial launch of BIOCERA-VET® Combo-Clean, a new reference for BIOCERA-VET, its comprehensive bone substitutes range, in Europe and United Kingdom. BIOCERA-VET® Combo-Clean will be available on our website (www.bioceravet.com).

Infections can be a major concern when it comes to orthopedic surgeries and can occur in 5% of these surgeries. In order to prevent damage to the bone, a treatment with antibiotics and removal of infected implants and materials is generally recommended. Also, preventive treatment can occur for high-risk surgeries (e.g., open fracture from a trauma or bite).

BIOCERA-VET® Combo-Clean is the solution to bring locally high concentration of antibiotics and to ensure stability thanks to its mechanical strength. To manage bone infections, it can be mixed with the 7 most commonly used antibiotics (covering all the most common germs involved in bone infection). In addition to its properties as bone substitute (i.e., mechanical strength, osteointegration and osteoconduction), and superior ergonomics (i.e., easy-to-prepare, highly injectable), BIOCERA-VET® Combo-Clean features optimal antibiotic release profile enabling a local but also long-lasting antimicrobial action for up to 30 days.

The combination of all these properties makes of BIOCERA-VET® Combo-Clean the first-of-its-kind sustained antibiotic releasing bone substitute.

About TheraVet SA

TheraVet is a veterinary biotechnology company specializing in osteoarticular treatments for companion animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from joint and bone diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris and Brussels, has its head office in Belgium (Gosselies) with a US subsidiary.

For more information, visit the TheraVet website or follow us on LinkedIn / Facebook / Twitter

About BIOCERA-VET

In close collaboration with an international scientific board, THERAVET® has developed a new line of calcium-phosphate and biological bone substitutes, BIOCERA-VET®. BIOCERA-VET® is a full range of innovative, easy-to-use, efficient & cost-effective bone substitutes indicated in bone surgeries where a bone graft is required and as a palliative alternative in the management of canine osteosarcoma. Based on extremely promising clinical results, this line offers the possibility of a better, more convenient and more efficient orthopedic surgery.

BIOCERA-VET® is declined in different lines:

  • BIOCERA-VET® BONE SURGERY RTU, a ready-to-use highly injectable self-hardening calcium-phosphate cement
  • BIOCERA-VET® SMARTGRAFT, a naturally osteoconductive bone graft
  • BIOCERA-VET® GRANULES, an affordable biocompatible calcium-phosphate bone substitute
  • BIOCERA-VET® OSTEOSARCOMA RTU, a ready-to-use highly injectable calcium-phosphate bone substitute for cementoplasty
  • BIOCERA-VET® COMBO-CLEAN, a local and long-lasting antibiotic delivery calcium-phosphate bone substitute

For more information, visit BIOCERA-VET website.

1 MIC: Minimum Inhibitory Concentration is the lowest concentration of an antibacterial agent which, under strictly controlled in vitro conditions, completely prevents visible growth of the test strain of an organism

 

Contacts

TheraVet
Chief Operating Officer
Sabrina Ena
investors@thera.vet
Tel: +32 (0) 71 96 00 43

Chief Corporate Officer
Julie Winand
investors@thera.vet

NewCap
Investor Relations and Financial Communications
Théo Martin / Nicolas Fossiez
theravet@newcap.eu
Tel: +33 (0)1 44 71 94 94

Press Relations
Arthur Rouillé
theravet@newcap.eu
Tel: +33 (0)1 44 71 00 15

NewCap Belgique
Press Relations
Laure-Eve Monfort
lemonfort@thera.vet
Tel: + 32 (0) 489 57 76 52

TheraVet

BOURSE:ALVET

Release Versions

Contacts

TheraVet
Chief Operating Officer
Sabrina Ena
investors@thera.vet
Tel: +32 (0) 71 96 00 43

Chief Corporate Officer
Julie Winand
investors@thera.vet

NewCap
Investor Relations and Financial Communications
Théo Martin / Nicolas Fossiez
theravet@newcap.eu
Tel: +33 (0)1 44 71 94 94

Press Relations
Arthur Rouillé
theravet@newcap.eu
Tel: +33 (0)1 44 71 00 15

NewCap Belgique
Press Relations
Laure-Eve Monfort
lemonfort@thera.vet
Tel: + 32 (0) 489 57 76 52

More News From TheraVet

Decision by Euronext to Classify the Asset Contribution of the H4 Orphan Pharma License to TheraVet as a Reverse Takeover

GOSSELIES, Belgium--(BUSINESS WIRE)--Regulatory News: EGEIRO Pharma (ISIN Code: BE0974387194 - Mnemonic: ALVET), a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs, in particular for Idiopathic Pulmonary Fibrosis, announces that it has been informed of Euronext’s decision to classify the asset contribution of a license from H4 Orphan Pharma to TheraVet S.A. as a reverse takeover (RTO). This decision is based on two major factors: the contribution o...

EGEIRO's Board of Directors Acknowledges the Resignation of Enrico Bastianelli and Modifies Its Governance

GOSSELIES, Belgium--(BUSINESS WIRE)--Regulatory News: EGEIRO Pharma (ISIN : BE0974387194 - mnemo : ALVET), a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs, notably in Idiopathic Pulmonary Fibrosis, announces that its Board of Directors meeting on November 15, 2024 has acknowledged the resignation of Enrico Bastianelli as a Director and has decided to modify its governance. Gaëtan Terrasse has been appointed Managing Director and Emmanuel Huynh C...

TheraVet Becomes EGEIRO Pharma

GOSSELIES, Belgium--(BUSINESS WIRE)--Regulatory News: TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, informs its shareholders that its Extraordinary General Meeting (“EGM”) was held on Monday October 28, 2024 at 10:00 am in the offices of the Berquin law firm, 11 avenue Lloyd George, 1000 Brussels, in the presence of Simon Wheeler, Chairman of the Board of Directors. The number of shares held by shareholders present, rep...
Back to Newsroom